ATC codes:
H02AB04
EMLc
Indication
Lymphoid leukaemia, not elsewhere classified
ICD11 code:
2C03.3
INN
Methylprednisolone
Medicine type
Chemical agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
40 mg per mL in 1 mL single-dose vial (as sodium succinate)
(EMLc)
;
40 mg per mL in 5 mL multi-dose vial (as sodium succinate)
(EMLc)
;
80 mg per mL in 1 mL single-dose vial (as sodium succinate)
(EMLc)
Sex
All
Age
Children (1 month - 12 years)
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methylprednisolone injection on the complementary list of the EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.